Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Experts Share What They're Going to Work on Improving in Practice This Year

February 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.

Dr. Biran on Post-ASCT Consolidation in Multiple Myeloma

February 1st 2020

Noa Biran, MD, physician, discusses elotuzumab (Empliciti) as post-autologous stem cell transplant consolidation in patients with high-risk myeloma.

Dr. Ghobrial on Triplet Regimen in Smoldering Myeloma

January 31st 2020

Irene Ghobrial, MD, discusses the combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone in smoldering multiple myeloma.

Dr. Paner on HORIZON Trial in Multiple Myeloma

January 30th 2020

Agne Paner, MD, director, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Dr. Hari on CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

January 30th 2020

Parameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

CAR-T, Novel Combos Continue to Show Benefit in Multiple Myeloma

January 29th 2020

Larry Anderson, MD, PhD, discusses emerging therapies for patients with multiple myeloma that were highlighted at the 2019 ASH Annual Meeting.

Real-World Use of BCMA-Targeted Therapy in Myeloma

January 29th 2020

BCMA-Targeted Approaches for Relapsed Myeloma

January 29th 2020

Coming Soon: Isatuximab + Pom/Dex for Relapsed Myeloma

January 29th 2020

Treatment Options for Lenalidomide-Refractory Myeloma

January 29th 2020

Outcomes for Relapsed/Refractory Myeloma

January 29th 2020

Maintenance Therapy for Multiple Myeloma

January 29th 2020

Considering Daratumumab-Based Quadruplets for Myeloma

January 29th 2020

Nuances of Using Frontline Daratumumab for Myeloma

January 29th 2020

Choosing Front-Line Therapy for Myeloma

January 29th 2020

CD38-Targeted Monoclonal Antibodies in Myeloma

January 29th 2020

Outcomes With Transplant in Myeloma

January 29th 2020

MRD as a Composite End Point in Myeloma

January 29th 2020

Transplant-Eligible Multiple Myeloma

January 29th 2020

Initial Therapy for High-Risk Myeloma

January 29th 2020